Could a common diabetes pill help hearts heal after a heart attack?

NCT ID NCT07621380

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the diabetes drug ertugliflozin, started within 72 hours of a first heart attack, can improve heart function in people with type 2 diabetes. About 476 adults will be randomly assigned to take the drug or receive standard care. Researchers will measure changes in a heart stress marker (NT-proBNP) and heart pumping ability over 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ertugliflozin (a diabetes drug that lowers blood sugar and may protect the heart)
What this could lead to: If it works, this could point toward a new standard treatment to protect the heart after a heart attack in people with type 2 diabetes.
What could go wrong: This is a phase 4 trial, so the drug is already approved for diabetes, but its benefit for heart attack recovery is unproven. Risks include genital infections and ketoacidosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS MYOCARDIAL INFARCTION

Contacts and locations

Locations

Zhongshan Hospital, Fudan University

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.